Log in
Enquire now
‌

Sigray, Inc. SBIR Phase I Award, September 2020

A SBIR Phase I contract was awarded to Sigray, Inc. in September, 2020 for $246,220.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health.

OverviewStructured DataIssuesContributors

Contents

sbir.gov/node/1915867
Is a
SBIR/STTR Awards
SBIR/STTR Awards

SBIR/STTR Award attributes

SBIR/STTR Award Recipient
Sigray, Inc.
Sigray, Inc.
0
Government Agency
0
Government Branch
National Institutes of Health
National Institutes of Health
0
Award Type
SBIR0
Contract Number (US Government)
1R44HL154950-010
Award Phase
Phase I0
Award Amount (USD)
246,2200
Date Awarded
September 1, 2020
0
End Date
March 31, 2021
0
Abstract

Project Summary/Abstract Chronic obstructive pulmonary disease (COPD) and lung cancer are the third and sixth most common causes of death worldwide. One major challenge is that there are no effective screening methods capable of early detection of these diseases and when these diseases are finally detected, they are often at advanced stages for which few effective treatment strategies exist. In the case of lung cancer, more than half of people die within the year of diagnosis. Darkfield (scattering-based) x-ray contrast has been recently demonstrated to provide exciting capabilities for early detection of lung pathologies, including cancer and COPD at doses comparable to conventional chest radiography. This contrast mechanism differs significantly from current approaches, which use the absorption of x-rays for contrast rather than the scattering of x-rays. Accessing information provided by this contrast mechanism requires an emerging grating-based x-ray technique called Talbot-Lau interferometry, which uses three sets of gratings (source, phase, and detector) to achieve contrast. However, a critical bottleneck for using this technique at the high x-ray energies (~60 keV) required for imaging through a human chest is a source grating with the aspect ratios required cannot be fabricated. We propose to develop a lung darkfield imaging prototype using a major x-ray source innovation that removes the need for the x-ray source grating to enable Talbot-Lau interferometry at high x-ray energies. The system will critically enable demonstrations of the clinical potential of darkfield radiography for early detection of lung pathologies. The proposed Phase I 6-month project is a proof-of-principle of a grating-less Talbot-Lau breadboard set-up on a phantom. The proposed Phase II 24-month project is to develop a complete prototype system and experimentally verify its performance.Project Narrative Lung diseases (e.g. lung cancer and chronic obstructive pulmonary disease) are devastating high mortality diseases that currently lack life-saving screening methods. This project proposes to develop a lung screening system that employs recent advances in darkfield x-ray imaging, which provides the sensitivity for critically needed early detection of lung diseases and at doses comparable to conventional chest x-rays. The implementation of a widespread screening method could enable early treatment and significantly impact survival outcomes of COPD and lung cancer, which are the fourth and seventh most common causes of death worldwide.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like Sigray, Inc. SBIR Phase I Award, September 2020

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.